

**Global AMR Innovators  
Conference  
22-24 September 2026  
Lisbon, Portugal**

**Preliminary Programme**





# Programme

**Tuesday, 22 September 2026**

---

12:00 – 13:00 Poster mounting

---

13:00 – 14:00 Session Hall

**Welcome and keynote lecture**

Introduction

tba

Keynote lecture 1

Valeria Gigante, Switzerland

Keynote lecture 2

Radu Botgros, Netherlands

---

14:00 – 14:30 Break

---

14:30 – 16:00 Session Hall

**Diagnostic development. When MICs don't make sense: designing development programmes when standard susceptibility testing breaks down**

Amy Mathers (Chair), USA

tba (Chair)

Proving it's not the drug: building the case against standard MIC testing?

tba

Designing 'non-standard' testing that reflects *in vivo* antimicrobial activity?

tba

Clinical trials without a standard test: logistics, risk, and reality

tba

From approval to adoption: diagnostic constraints and market reality

tba

---

16:00 – 16:30 Session Hall

**Lightning talks from poster presenters**

Shampa Das (Chair), UK

Taslimarif Saiyed (Chair), India

tba

---

16:30 – 16:45 Break

---

16:45 – 18:15 Poster area

**Poster session**

tba

---

18:15 – 18:30 Break

---

18:30 – 20:00 Session Hall

**Opening ceremony & reception**

tba

---



# Programme

Wednesday, 23 September 2026

08:30 – 10:00 Session Hall  
**Addressing global gaps: accelerating paediatric antibacterial drug development to meet unmet needs**  
Sumati Nambiar (Chair), USA  
Justin Green (Chair), Switzerland  
What do we need to do to ensure simultaneous adult and adolescent approvals?  
Marcela Ramirez, UK  
What can we do to expedite neonatal product development?  
tba  
How do we address the unmet needs of children in LMICs?  
tba

10:00 – 10:30 Break

10:30 – 10:45 Session Hall  
**CARB-X: A decade in review and a vision for the future**  
Colin McGoodwin (Chair), USA  
Vega Massignan (Chair), USA  
CARB-X: A decade in review and a vision for the future  
Richard Alm, USA

10:45 – 12:00 Session Hall  
**Challenges and Successes in the Clinical Development of Preventatives Against AMR**  
Colin McGoodwin (Chair), USA  
Vega Massignan (Chair), USA  
tba

12:00 – 13:00 Break

13:00 – 14:00 Session Hall  
**Decolonisation strategies coming of age: positioning them for success**  
Erin Duffy (Chair), USA  
tba (Chair)  
tba

14:00 – 14:30 Break

14:30 - 15:45 Session Hall  
**From aspiration to application: applying WHO target product profiles to antibiotic R&D**  
Valeria Gigante (Chair), Switzerland  
tba (Chair)

TPP 1: severe MDR Gram-negative infections (BSI, HABP/VABP) caused by CRAB, CRE, CRPA

Anand Kumar, India

TPP 2: resistant Gram-positive in high-risk patients caused by vancomycin-resistant enterococci (VRE), including vancomycin-resistant *E. faecium* (VREF)

tba

TPP N3: meningitis CA and HCA caused by MDR Gram-negative bacteria and methicillin-resistant *S. aureus*

Seun Makinde, USA

---

15:45 – 16:15

Break

---

16:15 – 16:45

Session Hall

**Lightning talks from poster presenters**

tba

---

16:45 – 17:30

Session Hall

**Keynote lecture**

tba (Chair)

tba

Karen Bush

---

17:30 – 17:45

Break

---

17:45 – 19:15

Poster area

**Poster session & reception**

tba

---

# Programme

Thursday, 24 September 2026

---

08:30 – 10:00 Session Hall  
**Phage therapy as a narrow-spectrum antimicrobial strategy: from product concept to late-stage clinical development**

John Rex (Chair), USA

Radu Botgros (Chair), Netherlands

tba

---

10:00 – 10:30 Break

---

10:30 – 12:00 Session Hall  
**Issues in clinical development**

David Paterson (Chair), Singapore

tba (Chair)

Lessons from a successful superiority trial

tba

Do we need Phase II clinical trials?

tba

Single arm trials: is LPAD still an option?

Sumathi Nambiar, USA

Panel discussion

All speakers

---

12:00 – 13:00 Break

---

13:00 – 14:00 Session Hall  
**Funding for clinical development**

David Paterson (Chair), Singapore

Richard Alm (Chair), USA

Sources of non-dilutive funding

Richard Alm, USA

AMR Action Fund: who should apply and when?

tba

Raising public funds via an IPO

tba

Is fund-raising for antibiotic trials any easier in a large company?

tba

---

14:00 – 14:30 Break

---

14:30 – 15:45 Session Hall  
**When innovation is not enough: access challenges in antibiotics**

Elena Breidenstein (Chair), UK

tba (Chair)

Setting the scene on global access to existing and new antibiotics

Yann Ferrisse, Switzerland

Access to existing antibiotics

tba

Access to reserve antibiotics

tba

Panel discussion

All speakers

---

15:45 – 16:15

Break

---

16:15 – 17:15

Session Hall

**Global insecurity and AMR: adapting narratives to shifting geopolitics**

Frédéric Peyrane (Chair), France

Jomana F. Musmar (Chair), USA

National resilience & response impact on federal decisions

tba

Force multipliers of AMR and impact on treatment decisions

tba

Investment, development, access, & policies in diverse settings

tba

---

17:15 – 17:45

Session Hall

**Closing remarks**

tba

---

